Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![biospace Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::21793154.png) BioSpace [@biospace](/creator/twitter/biospace) on x 25.1K followers
Created: 2025-06-23 15:29:59 UTC

After consistently failing to meet investor expectations, @novonordisk touted a safety profile for CagriSema in line with the GLP1-RA class, while reporting mid-stage data for its GLP1- and amylin-targeting drug amycretin that raised dosing questions.

#glp1 #obesity #biospace



XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1937171284774777046/c:line.svg)

**Related Topics**
[investment](/topic/investment)
[$nvo](/topic/$nvo)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/biospace/status/1937171284774777046)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

biospace Avatar BioSpace @biospace on x 25.1K followers Created: 2025-06-23 15:29:59 UTC

After consistently failing to meet investor expectations, @novonordisk touted a safety profile for CagriSema in line with the GLP1-RA class, while reporting mid-stage data for its GLP1- and amylin-targeting drug amycretin that raised dosing questions.

#glp1 #obesity #biospace

XXX engagements

Engagements Line Chart

Related Topics investment $nvo stocks healthcare

Post Link

post/tweet::1937171284774777046
/post/tweet::1937171284774777046